Pneumothorax

US-based medical device company Surgical Specialties has secured approval for its upgraded BioSentry Track Sealant System to launch in Europe.

The technology can now be used with a larger 17 gauge biopsy system for percutaneous transthoracic lung biopsy to reduce the risk of pneumothorax and other problems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lung biopsies are instrumental in determining patient-specific treatments and there has been an increased demand for larger tissue samples following the availability of more tumour specific therapies. Larger needles increase the risk of pneumothorax.

Frankfurt University, Germany professor Tomas Vogl said: "This change is of significant benefit for European radiologists because the addition of 17 gauge biopsy system compatibility allows larger tissue samples that give us better diagnosis and treatment options.

"Previously we have not had any preventative measures to reduce pneumothorax and related adverse events after a lung biopsy until now with BioSentry."

Pneumothorax is characterised by a collapsed lung caused when air leaks into the space between lung and chest wall.

This may be triggered by a blunt or penetrating chest injury, certain medical procedures, or damage from underlying lung disease.

"Previously we have not had any preventative measures to reduce pneumothorax and related adverse events after a lung biopsy until now with BioSentry."

The CE mark approved BioSentry System implants a self-expanding hydrogel plug into the pleural space following biopsy which expands to prevent air from leaking out causing pneumothorax.

The hydrogel plug is composed of a synthetic tissue-friendly polymer that fully reabsorbs into the body and its co-axial adapter adapts with the coaxial needle for the proper delivery and placement of the plug.

It’s delivery system features depth markings which allows accurate and consistent placement based on CT-guided measurements while the depth adjustment wheel and locking mechanism ensures a proper plug placement.

BioSentry offers new therapy option exhibiting positive clinical outcomes with the 19 gauge biopsy system, and now with a 17 gauge biopsy system.


Image: Illustration depicting pneumothorax. Photo: courtesy of BruceBlaus.